This guy is in denial. And he is very rude and condescending. It's people like him that make society an utter cesspool. He thinks 2011 shortfalls control current market moves. LOL! Cooper will eventually deliver something that will attract a BP as a new partner and that is the excitement over the abstract but shorts will always say it can't happen or never will. One day soon we will wake up to a new partner PR and idiots like him will be chasing shares up 40%. GL Run.
So Solasia sees value in something Ziopharm chose to shelf a few years back and you, Georgebushky are smarter than the scientists working for Solasia. What a freaking moron.
This is a perfect example of what a moron you are. Solasia obtained the license from ZIOP to develop and commercialize SP-02 so obviously they see some value in it. If Ziopharm had decided years ago that the money available to them would be better spent elsewhere at that time then that was their choice at the time but it doesn't mean the agent was useless. This is also a perfect example of a basher's attempt to rot anything positive reported on Ziopharm. You claim to be un-biased but anyone can see your agenda is to put Ziopharm down. Up yours you POS basher.
52 human patients enrolled across the spectrum in Glioma studies and ZIOP's Glioma study is not pre-clinical as you suggested. I now know exactly what your purpose here is now. Goodbye and good luck because I have just put you on ignore sir.
You can make lite of this if you would like. I do not know what your position of interest is here but you should also keep in mind that the world is watching these type of results due to the failure of past techniques using checkpoints and if ZIOP can prove safety here treating Glioma with an established checkpoint it will be very significant. And while you are correct in that many companies are presenting abstracts, not many are trying to go where all others have failed as in Glioma, the most insidious form of brain cancer. I think has the potential to be much more profound than you are willing to give it credit for, but again I am not aware of your incentives.
This is what he said......
"Cytokine IL-12 has import for other biology. Literature shows that checkpoint inhibitor data have been underwhelming for brain tumors. The likely reason is that there is not enough of an inflammatory signature within brain tumor for checkpoints to work. If you don’t have T cells in brain tumor it doesn’t matter how much checkpoint is swimming around the body. The answer is a pro-inflammatory cytokine like IL-12. If you put IL-12 in the tumor, you can call in the T-cells. Maybe more exciting as duality than monotherapy. MD Anderson are planning a single site exploratory trial in 2016”
Building upon foundation safely control & deliver IL-12 - combo with checkpoint inhibitors - pre clinical data demonstrates improved anti-tumor response in glioma (coming ASGCT in
Excuse me but on April 18th ZIOP will release the abstract we all have been waiting for. Glioma abstract . I am not touting anything but I curious why Cooper just announced this abstract that will be at ASCO in May to be out April 18th? I know you short bashers will say it is another pump and dump scheme but I am very intrigued.
Sentiment: Strong Buy
XBI down today but ZIOP recovered nicely. Shorts losing the handle on this again. A lot of buys on stock reports lately. Subscription type, not free. Good Luck Hope. I see what you mean about the greasy characters here but they are just about on every board like nasty little flies on a steaming pile of doggy dump.
They will hang on until it's too late. Just like the last four times this took off. Going to be fun for the longs here especially with dyckwads like the bashers here.
Sentiment: Strong Buy